.jpg)
UNIK Biotherapeutics is focused on the development of smarter and safer cancer medicines
UNIK’s distinctive portfolio of proprietary payload and antibody-drug conjugate (ADC) technologies comprises a suite of innovations designed to treat advanced stages of cancer. UNIK is a new spin-out company from the Institute of Cancer Therapeutics, University of Bradford, and boasts an experienced team with a proven track-record of success in the development and commercialisation of novel cancer therapeutics.
Our Science
UNIK’s technology is focused on development of novel payloads suitable for incorporation into biotherapeutic molecules, and next-generation ADCs that employ payloads that minimise toxic side-effects: antibody-prodrug conjugates (AproDCs) provide a new alternative to current ADCs. Our R&D technology has evolved over 20 years, from utilising our understanding of cancer biology to the design of tumour-targeted prodrugs rationalised to cause negligible side effects to healthy tissue. We are exploiting our vast experience and unique prodrug technologies to develop next-generation ADCs and AproDCs as safer immunoconjugates for the oncology market.
Our Team
The UNIK team has track record in innovative drug discovery, clinical evaluation of new oncology drugs, university spin-out companies and entrepreneurship. Our unique insight into payload, prodrug and ADC technologies means we are well-positioned to fully capitalise on the ADC platform technology to deliver next-generation of smarter and safer biotherapeutic molecules for oncology.
Co-founder and CEO
Co-founder and Director
Non-Executive Chair